Osteosarcoma Research Portal logoOsteosarcoma Research Portal

Cisplatin

. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.

← All drugs · Search the portal

Facts

Topic Fact Source (access date)
First US approval record Platinol (NDA 018057) original approval 19 Dec 1978, about 48 years Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA018057 (accessed 4 Nov 2026)
Mechanism A platinum compound that binds DNA strands together so they cannot be copied CRUK cisplatin (accessed 31 Oct 2026)
Use in osteosarcoma Part of MAP and AP first line; not named on US or UK labels (licensed for testicular, ovarian, bladder and other cancers) entries.json (portal export), sources opened 31 Oct to 3 Nov 2026; UK bone sarcoma guidelines 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC11723950/ (accessed 3 Nov 2026)
Combined with Methotrexate and doxorubicin (MAP); doxorubicin (AP); doxorubicin and ifosfamide (API-AI) UK bone sarcoma guidelines 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC11723950/ (accessed 3 Nov 2026)
Results EURAMOS-1 MAP cohort figures as above EURAMOS-1 full cohort, Smeland et al., Eur J Cancer 2019, doi:10.1016/j.ejca.2018.11.027 (PMID 30685685), abstract accessed 4 Nov 2026
Side effects Hearing loss and tinnitus, kidney damage, nerve damage, sickness, low blood counts; hearing tests and kidney checks during treatment CRUK (31 Oct 2026); Level 2 facts table
Owner and generic status Effect of platinum compounds on cell division reported by Rosenberg, Van Camp and Krigas (Nature, 1965); first US product Platinol (Bristol-Myers); now generic Rosenberg et al., Nature 1965, doi:10.1038/205698a0 (accessed 4 Nov 2026); Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA018057 (accessed 4 Nov 2026)
Regulatory UK: Hospira, PL 04515/0026, first authorised 6 Sep 1996; indications testicular, ovarian, bladder, head and neck, lung, cervical; osteosarcoma not named. EU (Ireland, national licence): Pfizer PA0822/199/001, same indications. China: domestic approvals e.g. Jiangsu Hansoh, Guoyao Zhunzi H20040813. In CSCO MAP eMC SmPC https://www.medicines.org.uk/emc/product/3788/smpc (accessed 4 Nov 2026); HPRA SmPC https://assets.hpra.ie/products/Human/22078/Licence_PA0822-199-001_09112026181407.pdf (accessed 16 Nov 2026); NMPA approval number H20040813 via yaopinnet.com mirror, https://www.yaopinnet.com/H/H13/H20040813.htm (accessed 4 Nov 2026); official NMPA register (datasearch.nmpa.gov.cn) returned HTTP 412 to automated access
Also worth noting Sodium thiosulfate (Pedmark, Fennec) US approval 20 Sep 2022 to reduce cisplatin hearing loss in children 1 month and older with localised, non-metastatic solid tumours; evidence from SIOPEL 6 (liver tumour) openFDA label API, https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22PEDMARK%22 (accessed 4 Nov 2026); Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA212937 (accessed 4 Nov 2026)

Hypotheses and open points (not established fact)